August 6, 2020 Life Science Tools M&A, Partnerships

Bio-Techne and Nanostring Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler

Curated Menu of Off-the-Shelf RNAscope Probes Provide Molecularly-Guided Region of Interest Selection for Use with the New NGS-Enabled Cancer Transcriptome Atlas MINNEAPOLIS and SEATTLE, Aug. 6, 2020 /PRNewswire/ — Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic markets and NanoString Technologies, Inc. (NASDAQ:NSTG), a leading... Read more

July 30, 2019 Cell Analysis Tools Clinical Research/Diagn. M&A, Partnerships

NanoString Technologies and Mayo Clinic Laboratories Enter Joint Development Agreement to Develop Novel Assays

SEATTLE and ROCHESTER, Minn., July 30, 2019 (GLOBE NEWSWIRE) — NanoString Technologies and Mayo Clinic Laboratories have announced a collaboration to develop clinical tests using NanoString’snew GeoMx Digital Spatial Profiler. GeoMx combines spatial and molecular profiling technologies by generating a whole tissue image at single cell resolution while also providing digital profiling data for tens to thousands of RNA or protein analytes for up... Read more

July 15, 2019 Clinical Research/Diagn. M&A, Partnerships

NanoString Collaborates with MODEL-AD Consortium to Accelerate Alzheimer’s Disease Research

nCounter Mouse AD Gene Expression Panel Applied to Characterize Five Novel Mouse Models New nCounter Human AD Gene Expression Panel Launched at AAIC 2019 SEATTLE, July 15, 2019 (GLOBE NEWSWIRE) —  NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a collaboration with the MODEL-AD consortium that has resulted in... Read more

May 30, 2019 Clinical Research/Diagn. M&A, Partnerships

NanoString Partners with Multiple Leading Contract Research Organizations to Provide Standardized PanCancer IO 360 Data Analysis Reports

Program Extends Ability of CAP CLIA Labs to Develop a Tumor Inflammation Signature Assay to Support Translational Research by Biopharmaceutical Companies SEATTLE, May 30, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced commercial partnerships with three Contract Research Organizations (CROs), including Covance, NeoGenomics Laboratories,... Read more

April 2, 2019 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

NanoString and Leica Biosystems to Co-Market GeoMx Digital Spatial Profiling and Leica’s BOND RX Platforms for High Throughput Spatial Analysis

Combined Workflow Provides Complete Solution for Rapid, Automated, and Highly Multiplexed Profiling of Protein and RNA Biomarkers in FFPE Samples SEATTLE and NEWCASTLE UPON TYNE, UK, April 02, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a comarketing agreement to promote and provide technical support for... Read more

April 1, 2019 Clinical Research/Diagn. M&A, Partnerships

NanoString and Abcam Enter Commercial Partnership to Provide Expanded Menu of Antibodies for GeoMx Digital Spatial Profiler

— Abcam to Develop Conjugated FFPE IHC Validated Antibodies Compatible with the GeoMx DSP — SEATTLE and CAMBRIDGE, UK, April 01, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a commercial agreement with Abcam plc (AIM:ABC), a global innovator in life science reagents and tools, for the manufacture... Read more

March 28, 2019 Life Science Tools M&A, Partnerships

Bio-Techne and NanoString Partner to Co-Develop Integrated Workflow for RNA Spatial Profiling

Integrated Workflow Combines NanoString’s GeoMx DSP High-Plex RNA Assays and Bio-Techne’s Highly Sensitive RNAscope Imaging Reagent Portfolio SEATTLE and MINNEAPOLIS, March 28, 2019 (GLOBE NEWSWIRE) — Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and NanoString Technologies, Inc.(NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic... Read more

March 27, 2019 Product Launch

NanoString Announces Commercial Launch of GeoMx Digital Spatial Profiler at the 2019 American Association of Cancer Research Conference

Complete Integrated Solution includes High-Throughput Instrument, Validated Protein & RNA Panels, and Integrated Data Analysis Software SEATTLE, March 27, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the commercial availability of the GeoMx™ Digital Spatial Profiler during the American Association of Cancer Research (AACR) conference being... Read more

March 25, 2019 Clinical Research/Diagn. Life Science Tools PR/Corporate

NanoString Technologies Announces Closing of Public Offering of 5,175,000 Shares of Common Stock Including Exercise in Full of Option to Purchase Additional Shares

SEATTLE, March 25, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the closing of its previously announced underwritten public offering of 5,175,000 shares of its common stock at a price to the public of $23.00 per share pursuant to its shelf registration statement. NanoString sold 3,175,000 shares of... Read more

March 19, 2019 Clinical Research/Diagn. Life Science Tools PR/Corporate

NanoString Technologies Announces Pricing of Public Offering of 4,500,000 Shares of Common Stock

SEATTLE, March 19, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $23.00 per share pursuant to its shelf registration statement. NanoString will sell 2,500,000 shares of common... Read more